>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

MNOV +19.1%, BWLD +18.3%, TREE +12%, TWTR +9.4%, ECHO +7.1%, STM+6.7%, TER +5.7%, IRDM +5%, NVCR +5%, AEM +4.2%, INVA +4%, BGG +4%,DCM +3.6%, LKQ +3.3%, SXCP +3.3%, SAN +3.2%, GDI +2.9%, MAA +2.7%,ABEV +2.6%, RS +2.5%, PTC +2.4%, ABB +2.3%, VSH +2.3%, SRPT +2.2%,LVS +2%, SAVE +2%, ELY +1.9%, GG +1.7%, SU +1.7%, EQT +1.7%, MCK+1.7%, WLL +1.6%, FTI +1.6%, VALE +1.6%, F +1.5%, RTN +1.5%, VLO+1.5%, XRX +1.5%, SBGL +1.4%, CSLT +1.2%, FNF +1.1%, PX +1.1%, O +1%,CSII +1%, CX +1%, QSR +1%, AFL +0.9%, MO +0.9%

Other news:

VTGN +33.3% (announces FDA has authorized the Co to proceed, under its Investigational New Drug application, with its planned Phase 2 clinical study of AV-101
MNOV +18.4% (announces that the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) achieved both primary endpoints)
TRVN +17% (announces publication of the results of APOLLO-1 and APOLLO-2 at the 2017 Annual Meeting of the American Society of Anesthesiologists from positive Phase 3 trials )
NNVC +6.3% (extended its agreement with SUNY Upstate Medical Center for further testing of its nanoviricides drug candidates against Shingles)
QTNT +5.4% (indicated higher after Highbridge Capital discloses increased passive stake to 9.92%)
TGTX +4.3% (announces results from the Phase 2 multicenter trial of TG-1101)
PSTI +4% (received approval from Israel's Ministry of Health to initiate a Phase I trial studying the company's PLX-R18 cell therapy)
AGEN +3.2% (CDC Advisory Committee on Immunization Practices voted in favor of three recommendations for the use of Shingrix containing QS-21 Stimulon for the prevention of shingles)
VERU +2.8% (files for $50 mln mixed securities shelf offering)
CZR +2% (LVS sympathy)
TSRO +1.8% (receives FDA approval for VARUBI IV )
WYNN +1.2% (LVS sympathy)

Analyst comments: